RLMD stock spikes as Steve Cohen's Point72 discloses stake (NASDAQ:RLMD)
seekingalpha.com
news
2022-10-17 17:33:20

aluxum/E+ via Getty Images Relmada Therapeutics (NASDAQ:RLMD) added more than 8% into afternoon trading Monday after Point72 Asset Management, run by billionaire fund manager Steven Cohen disclosed 7.3% ownership in the clinical-stage biotech. According to a 13-G filing submitted Monday, the hedge fund owns ~2.0M RLMD shares, including 68.8K shares underlying the call options as of Oct. 13. The announcement comes days after RLMD shares plunged ~79% after the company said its depression candidate REL-1017 failed to improve symptoms compared to the placebo and meet the main goal in a late-stage trial involving patients with major depressive disorder.
